Solulin increases clot stability in whole blood from humans and dogs with hemophilia

Blood

Volumn 119, Issue 15, 2012, Pages 3622-3628

  Foley, Jonathan H ^a,b   Petersen, Karl Uwe ^c   Rea, Catherine J ^a,d   Harpell, Lori ^e   Powell, Sandra ^e   Lillicrap, David ^e   Nesheim, Michael E ^e,f   Sørensen, Benny ^a,d,g  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VERMONT   (United States)

^c PAION Deutschland GmbH   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e QUEEN S UNIVERSITY   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTEIN C; SOLULIN; THROMBIN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

EID: 84859815893     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-392308     Document Type: Article

References (32)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. (Pubitemid 32497033)
2. Hoyer LW. Hemophilia A. N Engl J Med. 1994; 330(1):38-47.
3. Pollmann H, Richter H, Siegmund B. Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A. Haemophilia. 2004;10(5):676-678. (Pubitemid 39317780)
4. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev. 2004;18(2): 101-113. (Pubitemid 38380666)
5. Ikkala E, Helske T, Myllyla G, Nevanlinna HR, Pitkanen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79. Br J Haematol. 1982;52(1): 7-12. (Pubitemid 12028601)
6. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007; 110(3):815-825. (Pubitemid 47267416)
7. O'Mahony B, Black C. Expanding hemophilia care in developing countries. Semin Thromb Hemost. 2005;31(5):561-568. (Pubitemid 41642570)
8. Sørensen B, Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor-clinical outcome and laboratory observations. Thromb Haemost. 2010;103(6):1275-1276.
9. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost. 2007;5(12):2408-2414. (Pubitemid 350154350)
10. Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia. 2004;10(1):58-62. (Pubitemid 38195626)
11. Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008;111(2):672-679.
12. Waters EK, Genga RM, Schwartz MC, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood. 2011;117(20):5514-5522.
13. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69(4):491-497.
14. Rea CJ, Foley JH, Ingerslev J, Sorensen B. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost. 2011;9(3):510-516.
15. Weisel JW, Nagaswami C, Young TA, Light DR. The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem. 1996;271(49):31485- 31490.
16. Light DR, Glaser CB, Betts M, et al. The interaction of thrombomodulin with Ca2+. Eur J Biochem. 1999;262(2):522-533.
17. Pawar S, Fu Q, Wang J, et al. Targeting the endothelial thrombomodulin-protein C pathway to mitigate radiation lethality. Radiat Res Society. 2010; 56:73.
18. Foley JH, Cook PF, Nesheim ME. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites. J Biol Chem. 2011;286(22):19280-19286.
19. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88(10):3815-3823. (Pubitemid 26383103)
20. Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol. 1987;18(2):153-161. (Pubitemid 17024345)
21. Esmon CT, Esmon NL, Kurosawa S, Johnson AE. Interaction of thrombin with thrombomodulin. Ann N Y Acad Sci. 1986;485:215-220. (Pubitemid 17022498)
22. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982; 257(14):7944-7947. (Pubitemid 13241217)
23. Esmon CT, Johnson AE, Esmon NL. Initiation of the protein C pathway. Ann N Y Acad Sci. 1991; 614:30-43.
24. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996; 271(28):16603-16608. (Pubitemid 26239017)
25. Liu LW, Rezaie AR, Carson CW, Esmon NL, Esmon CT. Occupancy of anion binding exosite 2 on thrombin determines Ca2+ dependence of protein C activation. J Biol Chem. 1994;269(16): 11807-11812.
26. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem. 1999;274(8):5201-5212.
27. Hough C, Kamisue S, Cameron C, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost. 2002;87(4):659-665. (Pubitemid 34302955)
28. van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost. 2011;105(2):302- 312.
29. Wu C, Kim PY, Manuel R, et al. The roles of selected arginine and lysine residues of TAFI (Pro- CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem. 2009; 284(11):7059-7067.
30. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26(11):2445- 2453.
31. Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem. 2000;275(30):22942-22947. (Pubitemid 30646181)
32. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost. 2009;7(5):825-832.